LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
21 hedge funds and large institutions have $5.99M invested in LAVA Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 19 → 21 (+2)
0.57% less ownership
Funds ownership: 14.3% → 13.73% (-0.57%)
11% less capital invested
Capital invested by funds: $6.77M → $5.99M (-$775K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$88.2K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$87.8K |
| 3 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
+$77.8K |
| 4 |
Morgan Stanley
New York
|
+$38.1K |
| 5 |
VF
Virtu Financial
New York
|
+$35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$405K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$90.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$55.5K |
| 4 |
Millennium Management
New York
|
-$26.4K |
| 5 |
Walleye Capital
New York
|
-$20K |
LVTX Hedge Fund Activity: Q3 2024 in Review
21 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q3 2024, worth a combined $5.99M — down 11% from $6.77M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LVTX positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $88.2K. The largest seller was Sphera Funds Management, cutting an estimated $405K.
- 21 institutional investors held LAVA Therapeutics (LVTX) as of Q3 2024, up from 19 in Q2 2024.
- Funds reported $5.99M of LAVA Therapeutics stock for Q3 2024, down 11% quarter-over-quarter.
- 4 funds opened new LAVA Therapeutics positions in Q3 2024 and 2 closed out, a net change of +2 holders.
- The largest LAVA Therapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $88.2K added.
- The largest LAVA Therapeutics seller in Q3 2024 was Sphera Funds Management, an estimated $405K sold.
Based on aggregated 13F filings for Q3 2024.